Scarecrow Secures Patent For Supplement To Combat Cardiac Disorder In Animals

KUALA LUMPUR, Nov 12 (Bernama) -- Scarecrow Incorporated, a manufacturer engaging in the research, development, and distribution of supplements for animals, has obtained the world's first patent for Pinfenon (S), a product the company has been distributing since its founding in 2004.

According to a statement, the supplement is associated with a treatment drug and a prophylactic drug for lowering the atrial natriuretic peptide (ANP) as well as their manufacturing methods.

The supplements approved as drugs by the Japan Patent Office are subject to technical transfer in such products as food, shampoos, and essences as new means of allowing anyone to protect small dogs from cardiac disorders.

Mitral regurgitation, a cardiac disorder frequently observed in dogs around the world but particularly in Japan.

Many breeds of small dogs are genetically susceptible to the cardiac disorder, and valvular diseases of the heart, which include mitral regurgitation, are the third most common cause of death in elderly dogs (according to Anicom HD, Japan, 2023).

One of the indicators of the severity of this disease is ANP. This is a hormone primarily synthesised and stored in the part of the heart called the atrium before being secreted in the blood and can be measured by a blood test.

For this reason, ANP is also referred to as a cardiac biomarker. As a result, a patent was acquired for Pinfenon (S) after it was demonstrated to reduce the burden on the heart and lower the level of this ANP.

The main ingredient of Pinfenon (S) is a material extracted from the bark of pine trees called French maritime pine, which is cultivated only in the southwestern part of France.

It is a safe, water-soluble natural food product and a natural health ingredient with extremely high physiological activity, as well as contains supporting ingredients, such as fermented sesame extract and yeast extract, to further enhance the effect in the body of animals.

-- BERNAMA